AU2024293568A1 — Methods of treating chronic kidney disease (ckd) or ckd and hypertension with lorundrostat, or a combination of lorundrostat and a sglt2 inhibitor
Assigned to Mineralys Therapeutics Inc · Expires 2026-02-19 · 0y expired
What this patent protects
This invention provides methods of treating chronic kidney disease (CKD) or CKD and hypertension in a subject afflicted with CKD or CKD and hypertension, the method comprising administering to the subject an amount of lorundrostat or a pharmaceutically acceptable salt thereof onc…
USPTO Abstract
This invention provides methods of treating chronic kidney disease (CKD) or CKD and hypertension in a subject afflicted with CKD or CKD and hypertension, the method comprising administering to the subject an amount of lorundrostat or a pharmaceutically acceptable salt thereof once per day, wherein the amount is effective to treat CKD or CKD and hypertension in the subject.
Drugs covered by this patent
- Jardiance (empagliflozin) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.